Eisai Inc., of Woodcliff Lake, N.J., the U.S. pharmaceutical subsidiary of Tokyo-based Eisai Co. Ltd., appointed Adriana Herrera senior vice president, Americas Commercial Oncology. Read More
Sumitomo Dainippon Pharma Co. Ltd., of Osaka, Japan, said it signed a co-promotion and sales collaboration agreement with Novartis Pharma KK (NPKK), a unit of Novartis AG, of Basel, Switzerland, covering Equa (vildagliptin), a selective DPP-4 inhibitor, and Equmet (vildagliptin and metformin), a combination selective DPP-4 inhibitor and biguanide agent, to treat type 2 diabetes in Japan. Read More
HONG KONG – Invossa-K, a first-in-class cell and gene therapy that made headlines in 2017 when South Korean regulators cleared its use to treat osteoarthritis of the knee, is now on the verge of being phased out of the domestic market at least for one year and possibly for good, after being hit by a scandal involving its component ingredients. Read More
HONG KONG – Many agree that a biotech ecosystem is growing and approaching critical mass in China. But for the industry to leap, biotech scientists point to the need for more clinical talent and a better reimbursement system, while health care investors want to see the ecosystem maturing. Read More
Excited by early data on an investigational IL-4/IL-13 receptor antibody it in-licensed in 2014, Aslan Pharmaceuticals Pte. Ltd. has agreed to pay its source, CSL Ltd., as much as $780 million for full global rights to the asset, ASLAN-004, setting aside earlier plans to collar a global partner. Instead Aslan's team now plans to pay CSL $30 million upon starting a phase III study of the drug itself, after first tackling a multiple ascending-dose study in patients with moderate to severe atopic dermatitis (AD). Read More
HONG KONG – China's biotechnology industry and ecosystem is growing and approaching a critical mass in terms of innovation, financing and talent. That was the message May 29 during the second biotech summit held by the Hong Kong Stock Exchange (HKEX). Read More
HONG KONG – Y-biologics Inc., a South Korean biopharmaceutical firm, and U.S.-based biotechnology venture Genosco Inc. have recently signed a contract for cancer drugs research and development focused on testing the combination of immune checkpoint inhibitors and small-molecule cancer drugs. Read More
